Clinical trials: Stage II Breast Carcinoma
Breast Neoplasms
The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread
The main objective of the trial is to assess the efficacy of xentuzumab in combination with everolimus and exemestane over everolimus and exemestane in patients with HR+/ HER2- advanced or metastatic breast cancer and…
- Trial name
- NCT03659136
- Testing
- Xentuzumab, Everolimus, Exemestane
- Where
- 54 sites in United States, Australia and 9 more
- Volunteers
- 103 people
- Sponsor
- Boehringer Ingelheim
Breast Cancer
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
HER2-targeted therapy after the failure of trastuzumab treatment has become a new difficulty and challenge. Inetetamab, a new antibody to optimize the ADCC effect, has become one of the second-line treatment options after…
- Trial name
- NCT04681911
- Testing
- Inetetamab, Pyrotinib, Capecitabine
- Where
- China
- Volunteers
- 71 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Advanced Breast Cancer
Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast Cancer
Our study is aimed to evaluate the efficacy and safety of novel ADCs named SHR-A1811, SHR-A1921 and SHR-A2102 combined with adebrelimab in HER2-negative advanced breast cancer.
- Trial name
- NCT06433609
- Testing
- SHR-A1811, SHR-A1921, Adebrelimab
- Where
- China
- Volunteers
- 113 people
- Sponsor
- Beijing GoBroad Hospital
Estrogen Receptor Status, HER2/Neu Negative
Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer
This phase II trial studies how well alisertib with or without fulvestrant works in treating patients with endocrine-resistant breast cancer that has spread to other places in the body.
- Conditions
- Estrogen Receptor Status, HER2/Neu Negative, Invasive Breast Carcinoma, Postmenopausal
- Trial name
- NCT02860000
- Testing
- Alisertib, Fulvestrant, Laboratory Biomarker Analysis
- Where
- 8 sites in United States
- Volunteers
- 96 people
- Sponsor
- Mayo Clinic
Breast Cancer
Chemotherapy in Treating Women With Previously Treated Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Randomized phase II trial to compare the effectiveness of ISIS 5132 with ISIS 3521 in treating women…
- Trial name
- NCT00003236
- Testing
- ISIS 3521, ISIS 5132
- Where
- 6 sites in United States
- Sponsor
- Eastern Cooperative Oncology Group
Advanced Breast Cancer, HER2-positive Breast Cancer
DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] Disease
This is a multicenter, international, open-label, single-arm, multicohort, two-stage optimal Simon's design, phase II clinical trial
- Conditions
- Advanced Breast Cancer, HER2-positive Breast Cancer, Brain Metastases, Leptomeningeal Metastasis
- Trial name
- DEBBRAH (NCT04420598)
- Testing
- Trastuzumab deruxtecan
- Where
- 16 sites in Portugal, Spain
- Volunteers
- 41 people
- Sponsor
- MedSIR
Cancer
Voriconazole Compared With Itraconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
RATIONALE: Antifungals, such as voriconazole and itraconazole, may be effective in preventing fungal infections in patients who are undergoing allogeneic stem cell transplantation.
- Trial name
- NCT00079222
- Testing
- itraconazole, voriconazole
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
PIK3CA Mutated Advanced Solid Tumors, PIK3CA Amplified Advanced Solid Tumors
A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors
This was a multi-center, open-label, phase Ib/II study. The aim of the phase Ib part was to estimate the MTD(s) and/or identify the recommended phase II dose(s) (RP2Ds) for the combination of BYL719 and AMG 479 (ganitumab)…
- Trial name
- NCT01708161
- Testing
- BYL719, AMG 479
- Where
- 10 sites in United States, Belgium and 2 more
- Volunteers
- 47 people
- Sponsor
- Novartis Pharmaceuticals
HER2-negative Metastatic Breast Cancer
Adaptive Therapy for Post-Second-Line Advanced Breast Cancer
The primary objective of this study is to explore the efficacy and safety of adaptive therapy in the treatment of post-second-line metastatic breast cancer.
- Trial name
- NCT06533722
- Testing
- Gemcitabine, Vinorelbine, or Eribulin
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Sun Yat-sen University
Depression, Cancer
Mindfulness-based Intervention for Depressive Symptoms Sent Via Text (MINDSET)
The purpose of this study is to develop and test a new intervention to reduce depressive symptoms in post-treatment cancer participants.
- Conditions
- Depression, Cancer, Stage III Breast Cancer, Stage II Breast Cancer
- Trial name
- NCT06811454
- Testing
- MINDSET, Enhanced Usual Care (EUC)
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- Case Comprehensive Cancer Center
HER2-negative Breast Cancer, Hormone-receptor-positive Breast Cancer
DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Breast Cancer Patients
This study is being done to determine if there is a pattern associated with response to endocrine therapy alone and in combination with CDK4/6 inhibitor used for hormone receptor positive HER2 negative breast cancer.
- Conditions
- HER2-negative Breast Cancer, Hormone-receptor-positive Breast Cancer, Metastatic Breast Cancer, Anatomic Stage II Breast Cancer AJCC v8
- Trial name
- NCT06388122
- Testing
- Biospecimen Collection
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Mayo Clinic
Breast Cancer, Depression
Yoga or Educational Wellness Class for Women With Stage I, Stage II, or Stage III Breast Cancer Undergoing Chemotherapy
RATIONALE: Yoga and wellness classes may reduce fatigue and improve mood, sleep, and quality of life in women receiving chemotherapy for breast cancer.
- Conditions
- Breast Cancer, Depression, Fatigue, Sleep Disorders
- Trial name
- NCT00994279
- Testing
- Yoga, Education
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Wake Forest University Health Sciences
Breast Cancer
Trastuzumab (Herceptin), Bevacizumab, and Docetaxel (Taxotere) Trial in Stage IV Metastatic Breast Cancer (MBC) Patients
The primary objectives are to determine the progression-free survival (PFS) and to evaluate safety of the trastuzumab, bevacizumab and docetaxel regimen.
- Trial name
- NCT00428922
- Testing
- Trastuzumab, Bevacizumab, Docetaxel
- Where
- 3 sites in United States
- Volunteers
- 26 people
- Sponsor
- Bhuvaneswari Ramaswamy
Early-stage Breast Cancer, HER2 Positive Breast Cancer
Three Antidiarrheal Strategies in HER2+/HR+ Early Breast Cancer Patients Treated With Extended Adjuvant Neratinib
A Randomized Phase II Study to Evaluate the Incidence of Discontinuations due to Diarrhoea at 3 Cycles in patients with Early-stage HER2-positive (HER2+), Hormone Receptor-positive (HR+) Breast Cancer treated with Neratinib plus…
- Conditions
- Early-stage Breast Cancer, HER2 Positive Breast Cancer, Hormone Receptor Positive
- Trial name
- DIANER (NCT05252988)
- Testing
- Neratinib, Loperamide, Colesevelam
- Where
- 55 sites in Spain
- Volunteers
- 177 people
- Sponsor
- Spanish Breast Cancer Research Group
Positive Axillary Lymph Node, Stage 0 Breast Cancer AJCC v6 and v7
SCOUT Reflector for Tagging Lymph Nodes for Targeted Removal in Patients With Breast Cancer
This pilot clinical trial will evaluate whether the SCOUT reflector can be used to tag abnormal lymph nodes in patients with breast cancer prior to chemotherapy for targeted removal at the time of surgery.
- Conditions
- Positive Axillary Lymph Node, Stage 0 Breast Cancer AJCC v6 and v7, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7
- Trial name
- NCT03411070
- Testing
- Implanted Medical Device, Therapeutic Conventional Surgery
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Breast Cancer
Radiation Therapy in Treating Older Women Who Are Undergoing Surgery for Stage I or Stage II Breast Cancer
RATIONALE: Radiation therapy uses high-energy x rays to kill tumor cells. Giving radiation therapy after surgery may kill any tumor cells that remain after surgery.
- Trial name
- GERICO03 (NCT00104702)
- Testing
- adjuvant therapy, conventional surgery, radiation therapy
- Where
- 10 sites in France
- Volunteers
- 46 people
- Sponsor
- UNICANCER
Stage I Breast Cancer, Stage I Cervical Cancer
Carevive Survivor Care Planning System in Improving Quality of Life in Breast Cancer Survivors
This pilot clinical trial studies how well the Carevive Survivor Care Planning System works in improving quality of life in breast cancer survivors.
- Conditions
- Stage I Breast Cancer, Stage I Cervical Cancer, Stage I Ovarian Cancer, Stage I Uterine Corpus Cancer
- Trial name
- NCT03198286
- Testing
- Informational Intervention
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Breast Cancer
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage II or Stage IIIA Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Trial name
- NCT00003972
- Testing
- filgrastim, sargramostim, busulfan
- Where
- United States
- Volunteers
- 280 people
- Sponsor
- Fred Hutchinson Cancer Center
Endocrine Tumors, Non-Small Cell Lung Cancer
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
Background: A person s tumor is studied for mutations. When cells are found that can attack the mutation in a person s tumor, the genes from those cells are studied to find the parts that make the attack possible.
- Conditions
- Endocrine Tumors, Non-Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer
- Trial name
- NCT03412877
- Testing
- Cyclophosphamide, Fludarabine, Aldesleukin
- Where
- United States
- Volunteers
- 285 people
- Sponsor
- National Cancer Institute (NCI)
Estrogen Receptor-positive Breast Cancer, Musculoskeletal Complications
A Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)
E1Z11 is a study to determine whether certain genetic information can predict which breast cancer patients will discontinue treatment with aromatase inhibitors (AIs) due to the development of musculoskeletal symptoms (MSS).
- Conditions
- Estrogen Receptor-positive Breast Cancer, Musculoskeletal Complications, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer
- Trial name
- NCT01824836
- Testing
- anastrozole
- Where
- 2 sites in United States
- Volunteers
- 1,046 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.